DSIP - Delta Sleep-Inducing Peptide X 5mg
Regular price
Rs. 7,255
- Unit price
- per
100% Authentic
Made in USA
Authorised distributor
1-5 Days delivery
DSIP - Delta Sleep-Inducing Peptide X 5mg
Regular price
Rs. 7,255
- Unit price
- per
Price includes all duties and taxes
SKU: DSIP5
FMI's Choice
DSIP (Delta Sleep‑Inducing Peptide): It is a naturally occurring nonapeptide (Trp‑Ala‑Gly‑Gly‑Asp‑Ala‑Ser‑Gly‑Glu) first isolated in rabbits in the 1970s. It is named for its ability to promote slow‑wave (delta) sleep in experimental animals and has been studied across species including humans, rabbits, rats, and mice. Research suggests DSIP may play broader roles in neuroendocrine regulation, stress response, pain modulation, and immune function.
Mechanistic Claims
- Sleep Regulation: Enhances delta and spindle EEG activity, supporting deep sleep stages.
- Neuroendocrine Effects: Investigated for modulation of hypothalamic–pituitary function and stress response.
- Pain Modulation: Preclinical studies suggest potential analgesic properties.
- Immune Function: Early research indicates possible immunomodulatory activity.
- Systemic Role: Mechanism of action remains under investigation, with evidence pointing to multiple physiological pathways.
Research Applications
- Sleep physiology and insomnia research
- Neuroendocrine and stress regulation studies
- Pain and nociception models
- Immune system investigations
- Exploratory therapeutic studies in depression and chronic conditions
DSIP Research
Delta sleep-inducing peptide (DSIP) is a neuropeptide consisting of nine amino acids (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) that was first isolated from the cerebral venous blood of rabbits during sleep in the 1970s.
As its name suggests, DSIP was initially identified for its apparent ability to promote slow-wave (delta) sleep, which is the deepest stage of non-REM sleep. Subsequent research has revealed its effects may be more complex and potentially extend beyond sleep regulation.
DSIP has been studied for various potential physiological roles, including:
- Stress response and adaptation
- Pain modulation
- Immune system regulation
- Antioxidant properties
- Effects on endocrine function
DSIP has been investigated for potential applications in sleep disorders, pain management, and substance withdrawal syndromes.
DSIP and Sleep Regulation
DSIP is known for its ability to induce delta sleep, a type of non-REM sleep characterized by slow-wave EEG patterns. It has been shown to promote sleep in several species, including rabbits, rats, mice, and humans, with varying effects on REM sleep in cats1.
DSIP has been shown to influence neurotransmitter levels, including serotonin (5-HT), glutamate, dopamine, and melatonin, which are crucial for sleep regulation2. It also affects electrophysiological activity, circadian rhythms, and hormonal levels, indicating its broad impact on physiological processes3.
DSIP promotes sleep in a species-specific manner, with varying effects on different types of sleep across species. In clinical trials, DSIP has been shown to normalize disturbed sleep and improve alertness and performance during wakefulness4.
Despite its known effects, the physiological role of DSIP remains unclear, partly due to the lack of identification of its gene and receptor. The existence of DSIP-like peptides with similar biological activity has been hypothesized5.
DSIP and Pain Management
In clinical studies, DSIP administration resulted in a notable reduction in pain levels among patients with various pain syndromes, including migraines, vasomotor headaches, chronic tinnitus, and psychogenic pain attacks6. The peptide not only reduced pain severity but also decreased the duration and frequency of pain episodes, suggesting its potential as a therapeutic agent for chronic pain management7.
DSIP also influences circadian rhythms related to pain perception. In studies with rats, DSIP administration altered the circadian pain threshold, increasing it during both light and dark periods. This effect was not sensitive to naloxone, indicating a distinct mechanism from its opioid-mediated antinociceptive effects8.
DSIP and Withdrawal Symptoms
DSIP has shown promising results in treating withdrawal symptoms in both alcohol and opiate addicts. In a study involving 67 patients, DSIP treatment resulted in a beneficial effect in 48 out of 49 evaluable patients. The treatment led to an immediate and lasting suspension of somatic symptoms, with anxiety resolving more slowly9.
Another study with 107 inpatients reported that DSIP treatment led to a marked and rapid improvement in clinical symptoms for 97% of opiate addicts and 87% of alcohol addicts, although anxiety decreased more slowly10.
References
- Pollard, B., & Pomfrett, C. (2001). Delta sleep-inducing peptide.. European journal of anaesthesiology, 18 7, 419-22 . https://doi.org/10.1046/J.1365-2346.2001.00917.X.
- Mu, X., Qu, L., Yin, L., Wang, L., Liu, X., & Liu, D. (2024). Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1439536.
- Graf, M., & Kastin, A. (1986). Delta-sleep-inducing peptide (DSIP): An update. Peptides, 7, 1165-1187. https://doi.org/10.1016/0196-9781(86)90148-8.
- Schneider-Helmert, D., & Schoenenberger, G. (1983). Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep.. Neuropsychobiology, 9 4, 197-206 . https://doi.org/10.1159/000117964.
- Kovalzon, V., & Strekalova, T. (2006). Delta sleep‐inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry, 97. https://doi.org/10.1111/j.1471-4159.2006.03693.x.
- Larbig, W., Gerber, W., & Schoenenberger, G. (1987). Peptidergic Pain Reducing Effects Of The Delta-Sleep-Inducing Peptide (Dsip) In Headache And Other Pain Syndroms. Cephalalgia, 7, 46 – 48. https://doi.org/10.1177/03331024870070S614.
- Larbig, W., Gerber, W., Kluck, M., & Schoenenberger, G. (1984). Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study.. European neurology, 23 5, 372-85 . https://doi.org/10.1159/000115716.
- Yehuda, S., & Carasso, R. (1987). The effects of DSIP on pain threshold during light and dark periods in rats are not naloxone-sensitive.. The International journal of neuroscience, 37 1-2, 85-8 . https://doi.org/10.3109/00207458708991805.
- Dick, P., Grandjean, M., & Tissot, R. (1983). Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors.. Neuropsychobiology, 10 4, 205-8 . https://doi.org/10.1159/000118012.
- Dick, P., Costa, C., Fayolle, K., Grandjean, M., Khoshbeen, A., & Tissot, R. (1984). DSIP in the treatment of withdrawal syndromes from alcohol and opiates.. European neurology, 23 5, 364-71 . https://doi.org/10.1159/000115715.
Label--Peptide Information
| Property | Value |
|---|---|
| Peptide Sequence | Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu |
| Molecular Formula | C35H48N10O15 |
| Molecular Weight | 848.8 g/mol |
| CAS Number | 62568-57-4 |
| PubChem CID | 68816 |
| Synonyms | Emideltide, 62568-57-4, DELTA SLEEP INDUCING PEPTIDE, DSIP nonapeptide |
Dosage--This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.
Additional Taxes may apply for shipping to GCC
100% Authentic
Made in USA
Authorised distributor
1 - 5 days delivery
Click to read - How we deliver to India
Disclaimer
: Not a diet substitute. Seek Medical guidance if unsure before use.
DSIP (Delta Sleep‑Inducing Peptide): It is a naturally occurring nonapeptide (Trp‑Ala‑Gly‑Gly‑Asp‑Ala‑Ser‑Gly‑Glu) first isolated in rabbits in the 1970s. It is named for its ability to promote slow‑wave (delta) sleep in experimental animals and has been studied across species including humans, rabbits, rats, and mice. Research suggests DSIP may play broader roles in neuroendocrine regulation, stress response, pain modulation, and immune function.
Mechanistic Claims
- Sleep Regulation: Enhances delta and spindle EEG activity, supporting deep sleep stages.
- Neuroendocrine Effects: Investigated for modulation of hypothalamic–pituitary function and stress response.
- Pain Modulation: Preclinical studies suggest potential analgesic properties.
- Immune Function: Early research indicates possible immunomodulatory activity.
- Systemic Role: Mechanism of action remains under investigation, with evidence pointing to multiple physiological pathways.
Research Applications
- Sleep physiology and insomnia research
- Neuroendocrine and stress regulation studies
- Pain and nociception models
- Immune system investigations
- Exploratory therapeutic studies in depression and chronic conditions
DSIP Research
Delta sleep-inducing peptide (DSIP) is a neuropeptide consisting of nine amino acids (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) that was first isolated from the cerebral venous blood of rabbits during sleep in the 1970s.
As its name suggests, DSIP was initially identified for its apparent ability to promote slow-wave (delta) sleep, which is the deepest stage of non-REM sleep. Subsequent research has revealed its effects may be more complex and potentially extend beyond sleep regulation.
DSIP has been studied for various potential physiological roles, including:
- Stress response and adaptation
- Pain modulation
- Immune system regulation
- Antioxidant properties
- Effects on endocrine function
DSIP has been investigated for potential applications in sleep disorders, pain management, and substance withdrawal syndromes.
DSIP and Sleep Regulation
DSIP is known for its ability to induce delta sleep, a type of non-REM sleep characterized by slow-wave EEG patterns. It has been shown to promote sleep in several species, including rabbits, rats, mice, and humans, with varying effects on REM sleep in cats1.
DSIP has been shown to influence neurotransmitter levels, including serotonin (5-HT), glutamate, dopamine, and melatonin, which are crucial for sleep regulation2. It also affects electrophysiological activity, circadian rhythms, and hormonal levels, indicating its broad impact on physiological processes3.
DSIP promotes sleep in a species-specific manner, with varying effects on different types of sleep across species. In clinical trials, DSIP has been shown to normalize disturbed sleep and improve alertness and performance during wakefulness4.
Despite its known effects, the physiological role of DSIP remains unclear, partly due to the lack of identification of its gene and receptor. The existence of DSIP-like peptides with similar biological activity has been hypothesized5.
DSIP and Pain Management
In clinical studies, DSIP administration resulted in a notable reduction in pain levels among patients with various pain syndromes, including migraines, vasomotor headaches, chronic tinnitus, and psychogenic pain attacks6. The peptide not only reduced pain severity but also decreased the duration and frequency of pain episodes, suggesting its potential as a therapeutic agent for chronic pain management7.
DSIP also influences circadian rhythms related to pain perception. In studies with rats, DSIP administration altered the circadian pain threshold, increasing it during both light and dark periods. This effect was not sensitive to naloxone, indicating a distinct mechanism from its opioid-mediated antinociceptive effects8.
DSIP and Withdrawal Symptoms
DSIP has shown promising results in treating withdrawal symptoms in both alcohol and opiate addicts. In a study involving 67 patients, DSIP treatment resulted in a beneficial effect in 48 out of 49 evaluable patients. The treatment led to an immediate and lasting suspension of somatic symptoms, with anxiety resolving more slowly9.
Another study with 107 inpatients reported that DSIP treatment led to a marked and rapid improvement in clinical symptoms for 97% of opiate addicts and 87% of alcohol addicts, although anxiety decreased more slowly10.
References
- Pollard, B., & Pomfrett, C. (2001). Delta sleep-inducing peptide.. European journal of anaesthesiology, 18 7, 419-22 . https://doi.org/10.1046/J.1365-2346.2001.00917.X.
- Mu, X., Qu, L., Yin, L., Wang, L., Liu, X., & Liu, D. (2024). Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1439536.
- Graf, M., & Kastin, A. (1986). Delta-sleep-inducing peptide (DSIP): An update. Peptides, 7, 1165-1187. https://doi.org/10.1016/0196-9781(86)90148-8.
- Schneider-Helmert, D., & Schoenenberger, G. (1983). Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep.. Neuropsychobiology, 9 4, 197-206 . https://doi.org/10.1159/000117964.
- Kovalzon, V., & Strekalova, T. (2006). Delta sleep‐inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry, 97. https://doi.org/10.1111/j.1471-4159.2006.03693.x.
- Larbig, W., Gerber, W., & Schoenenberger, G. (1987). Peptidergic Pain Reducing Effects Of The Delta-Sleep-Inducing Peptide (Dsip) In Headache And Other Pain Syndroms. Cephalalgia, 7, 46 – 48. https://doi.org/10.1177/03331024870070S614.
- Larbig, W., Gerber, W., Kluck, M., & Schoenenberger, G. (1984). Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study.. European neurology, 23 5, 372-85 . https://doi.org/10.1159/000115716.
- Yehuda, S., & Carasso, R. (1987). The effects of DSIP on pain threshold during light and dark periods in rats are not naloxone-sensitive.. The International journal of neuroscience, 37 1-2, 85-8 . https://doi.org/10.3109/00207458708991805.
- Dick, P., Grandjean, M., & Tissot, R. (1983). Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors.. Neuropsychobiology, 10 4, 205-8 . https://doi.org/10.1159/000118012.
- Dick, P., Costa, C., Fayolle, K., Grandjean, M., Khoshbeen, A., & Tissot, R. (1984). DSIP in the treatment of withdrawal syndromes from alcohol and opiates.. European neurology, 23 5, 364-71 . https://doi.org/10.1159/000115715.
Peptide Information
| Property | Value |
|---|---|
| Peptide Sequence | Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu |
| Molecular Formula | C35H48N10O15 |
| Molecular Weight | 848.8 g/mol |
| CAS Number | 62568-57-4 |
| PubChem CID | 68816 |
| Synonyms | Emideltide, 62568-57-4, DELTA SLEEP INDUCING PEPTIDE, DSIP nonapeptide |
This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.
